CoChat
Sign Up
Cited by 47Phytoestrogen effects and researchNutritional Studies and DietCancer Risks and Factors

Effect of soybean on breast cancer according to receptor status: a case-control study in Japan

Open access
Suzuki, Takeshi, Matsuo, Keitaro, Tsunoda, Nobuyuki, Hirose, Kaoru, Hiraki, Akio, Kawase, Takakazu, Yamashita, Toshinari, Iwata, Hiroji +2 more·2008·International Journal of Cancer
DOI 10.1002/ijc.23644
Open this paper in CoChat — free accountOpen PDF

Abstract

The possible association of high soy food consumption with low incidence of breast cancer in Asian countries has been widely investigated, but findings from epidemiologic studies have been inconsistent. Breast cancers defined by receptor status, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) may have distinct etiologic factors. Here, we conducted a case–control study to clarify associations between intake of soybean products and breast cancer risk according to receptor status. A total of 678 breast cancer cases and 3,390 age‐ and menopausal status‐matched noncancer controls were included. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated using conditional logistic models adjusted for potential confounders. On analysis according to receptor status, we observed a significantly reduced risk of ER‐positive (ER+) (top tertile OR = 0.74; 95% CI, 0.58–0.94; trend p = 0.01) and HER2‐negative (HER2−) tumors (top tertile OR = 0.78; 95% CI, 0.61–0.99; trend p = 0.04). Further, when the 3 receptors were jointly examined, a reduced risk was observed only in patients with ER+/PR+/HER2− tumor (top tertile OR = 0.73; 95% CI, 0.54–0.97; trend p = 0.03). These findings indicate that the protective effect of soy against breast cancer risk differs by receptor status. © 2008 Wiley‐Liss, Inc.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.23644

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Eight of 12 (67%) studies examining high soy food or protein and six of seven (86%) studies examining high soy isoflavones reported inverse associations between soy and breast cancer risk.

    “Eight of 12 (67%) studies examining high soy food or protein [45,46,61,64,72,77,78,81] and six of seven (86%) studies examining high soy isoflavones [42,43,45,75,77,81] reported inverse associations between soy and breast cancer risk.”

    From Soy, Red Clover, and Isoflavones and Breast Cancer: A Systematic Review (2013) · cites this paper as [72]

    The Results (page not supplied) report an inverse association between soybean-product intake and overall breast cancer risk, so this paper supports its inclusion among the soy-food studies reporting an inverse association. The Assessment of soybean intake section describes measuring soy foods, not isoflavone intake. This paper also does not establish the citing sentence’s counts of eight of 12 and six of seven studies. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

  • Among case-control studies reporting odds ratios with confidence intervals, 11 of 19 (58%) showed significant inverse relationships between soy food or protein intake and breast cancer risk.

    “Of the 19 studies, 11 (58%) showed significant inverse relationships between soy food or protein intake and risk of breast cancer [44-46,61,64,71-73,77,78,81].”

    From Soy, Red Clover, and Isoflavones and Breast Cancer: A Systematic Review (2013) · cites this paper as [72]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 43

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
  2. Trock BJ, Hilakivi-Clarke L, Clarke R. Meta-analysis of soy intake and breast cancer risk. J Natl Cancer Inst 2006;98:459-71.
  3. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-502.
  4. Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moor- man PG. Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol 2000;151:703-14.
  5. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. Risk factors for breast cancer according to estrogen and progesterone re- ceptor status. J Natl Cancer Inst 2004;96:218-28.
  6. Nichols HB, Trentham-Dietz A, Love RR, Hampton JM, Hoang Anh PT, Allred DC, Mohsin SK, Newcomb PA. Differences in breast can- cer risk factors by tumor marker subtypes among premenopausal Viet- namese and Chinese women. Cancer Epidemiol Biomarkers Prev 2005;14:41-7.
  7. Gammon MD, Hibshoosh H, Terry MB, Bose S, Schoenberg JB, Brinton LA, Bernstein JL, Thompson WD. Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women. Cancer Epidemiol Biomarkers Prev 1999;8:413-9.
  8. Huang WY, Newman B, Millikan RC, Conway K, Hulka BS, Schell MJ, Liu ET. Risk of breast cancer according to the status of HER-2/ neu oncogene amplification. Cancer Epidemiol Biomarkers Prev 2000;9:65-71.
  9. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplon- ska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin- Mikolajczak A, Zatonski W, Cartun R, et al. Differences in risk fac- tors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 2007;16:439-43.
  10. Tajima K, Hirose K, Inoue M, Takezaki T, Hamajima N, Kuroishi T. A model of practical cancer prevention for out-patients visiting a hospital: the hospital-based epidemiologic research program at Aichi Cancer Center (HERPACC). Asian Pac J Cancer Prev 2000; 1:35-47.
  11. Hamajima N, Matsuo K, Saito T, Hirose K, Inoue M, Takezaki T, Kuroishi T, Tajima K. Gene-environment interactions and polymor- phism studies of cancer risk in the hospital-based epidemiologic research program at Aichi Cancer Center II (HERPACC-II). Asian Pac J Cancer Prev 2001;2:99-107.
  12. Inoue M, Tajima K, Hirose K, Hamajima N, Takezaki T, Kuroishi T, Tominaga S. Epidemiological features of first-visit outpatients in Ja- pan: comparison with general population and variation by sex, age, and season. J Clin Epidemiol 1997;50:69-77.
  13. Inoue M, Tajima K, Hirose K, Hamajima N, Takezaki T, Hirai T, Kato T, Ohno Y. Subsite-specific risk factors for colorectal cancer: a hospital-based case-control study in Japan. Cancer Causes Control 1995;6:14-22.
  14. Tokudome S, Ikeda M, Tokudome Y, Imaeda N, Kitagawa I, Fujiwara N. Development of data-based semi-quantitative food frequency ques- tionnaire for dietary studies in middle-aged Japanese. Jpn J Clin Oncol 1998;28:679-87.
  15. Tokudome Y, Goto C, Imaeda N, Hasegawa T, Kato R, Hirose K, Tajima K, Tokudome S. Relative validity of a short food frequency questionnaire for assessing nutrient intake versus three-day weighed diet records in middle-aged Japanese. J Epidemiol 2005;15:135- 45.
  16. Imaeda N, Goto C, Tokudome Y, Hirose K, Tajima K, Tokudome S. Reproducibility of a short food frequency questionnaire for Japanese general population. J Epidemiol 2007;17:100-7.
  17. Quenneville LA, Phillips KA, Ozcelik H, Parkes RK, Knight JA, Goodwin PJ, Andrulis IL, O'Malley FP. HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry. Cancer 2002;95:2068-75.
  18. Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF. The pathology of familial breast cancer: pre- dictive value of immunohistochemical markers estrogen receptor, pro- gesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002;20:2310-8.
  19. Willett W, Stampfer MJ. Total energy intake: implications for epide- miologic analyses. Am J Epidemiol 1986;124:17-27.
  20. Yu H, Harris RE, Gao YT, Gao R, Wynder EL. Comparative epidemi- ology of cancers of the colon, rectum, prostate and breast in Shanghai, China versus the. United States. Int J Epidemiol 1991;20:76-81.
  21. Yamamoto S, Sobue T, Kobayashi M, Sasaki S, Tsugane S. Soy, iso- flavones, and breast cancer risk in Japan. J Natl Cancer Inst 2003;95: 906-13.
  22. Wu AH, Ziegler RG, Horn-Ross PL, Nomura AM, West DW, Kolonel LN, Rosenthal JF, Hoover RN, Pike MC. Tofu and risk of breast can- cer in Asian-Americans. Cancer Epidemiol Biomarkers Prev 1996;5:901-6.
  23. Wu AH, Wan P, Hankin J, Tseng CC, Yu MC, Pike MC. Adolescent and adult soy intake and risk of breast cancer in Asian-Americans. Carcinogenesis 2002;23:1491-6.
  24. dos Santos Silva I, Mangtani P, McCormack V, Bhakta D, McMichael AJ, Sevak L. Phyto-oestrogen intake and breast cancer risk in South Asian women in England: findings from a population-based case-con- trol study. Cancer Causes Control 2004;15:805-18.
  25. Lee HP, Gourley L, Duffy SW, Esteve J, Lee J, Day NE. Risk factors for breast cancer by age and menopausal status: a case-control study in Singapore. Cancer Causes Control 1992;3:313-22.
  26. Linseisen J, Piller R, Hermann S, Chang-Claude J. Dietary phytoes- trogen intake and premenopausal breast cancer risk in a German case-control study. Int J Cancer 2004;110:284-90.
  27. Hirose K, Imaeda N, Tokudome Y, Goto C, Wakai K, Matsuo K, Ito H, Toyama T, Iwata H, Tokudome S, Tajima K. Soybean products and reduction of breast cancer risk: a case-control study in Japan. Br J Cancer 2005;93:15-22.
  28. Horn-Ross PL, Hoggatt KJ, West DW, Krone MR, Stewart SL, Anton H, Bernstei CL, Deapen D, Peel D, Pinder R, Reynolds P, Ross RK, et al. Recent diet and breast cancer risk: the California Teachers Study (USA). Cancer Causes Control 2002;13:407-15.
  29. Nishio K, Niwa Y, Toyoshima H, Tamakoshi K, Kondo T, Yatsuya H, Yamamoto A, Suzuki S, Tokudome S, Lin Y, Wakai K, Hamajima N, et al. Consumption of soy foods and the risk of breast cancer: find- ings from the Japan Collaborative Cohort (JACC) study. Cancer Causes Control 2007;18:801-8.
  30. Yuan JM, Wang QS, Ross RK, Henderson BE, Yu MC. Diet and breast cancer in Shanghai and Tianjin, China. Br J Cancer 1995;71: 1353-8.
  31. Ingram D, Sanders K, Kolybaba M, Lopez D. Case-control study of phyto-oestrogens and breast cancer. Lancet 1997;350:990-4.
  32. Dai Q, Shu XO, Jin F, Potter JD, Kushi LH, Teas J, Gao YT, Zheng W. Population-based case-control study of soyfood intake and breast cancer risk in Shanghai. Br J Cancer 2001;85:372-8.
  33. Horn-Ross PL, John EM, Lee M, Stewart SL, Koo J, Sakoda LC, Shiau AC, Goldstein J, Davis P, Perez-Stable EJ. Phytoestrogen con- sumption and breast cancer risk in a multiethnic population: the Bay Area Breast Cancer Study. Am J Epidemiol 2001;154:434-41.
  34. Grace PB, Taylor JI, Low YL, Luben RN, Mulligan AA, Botting NP, Dowsett M, Welch AA, Khaw KT, Wareham NJ, Day NE, Bingham SA. Phytoestrogen concentrations in serum and spot urine as bio- markers for dietary phytoestrogen intake and their relation to breast cancer risk in European prospective investigation of cancer and nutri- tion-norfolk. Cancer Epidemiol Biomarkers Prev 2004;13:698-708.
  35. Shannon J, Ray R, Wu C, Nelson Z, Gao DL, Li W, Hu W, Lampe J, Horner N, Satia J, Patterson R, Fitzgibbons D, et al. Food and botani- cal groupings and risk of breast cancer: a case-control study in Shang- hai, China. Cancer Epidemiol Biomarkers Prev 2005;14:81-90.
  36. Bosetti C, Spertini L, Parpinel M, Gnagnarella P, Lagiou P, Negri E, Franceschi S, Montella M, Peterson J, Dwyer J, Giacosa A, La Vec- chia C. Flavonoids and breast cancer risk in Italy. Cancer Epidemiol Biomarkers Prev 2005;14:805-8.
  37. Enger SM, Ross RK, Paganini-Hill A, Carpenter CL, Bernstein L. Body size, physical activity, and breast cancer hormone receptor sta- tus: results from two case-control studies. Cancer Epidemiol Bio- markers Prev 2000;9:681-7.
  38. Maskarinec G, Franke AA, Williams AE, Hebshi S, Oshiro C, Mur- phy S, Stanczyk FZ. Effects of a 2-year randomized soy intervention on sex hormone levels in premenopausal women. Cancer Epidemiol Biomarkers Prev 2004;13:1736-44.
  39. An J, Tzagarakis-Foster C, Scharschmidt TC, Lomri N, Leitman DC. Estrogen receptor beta-selective transcriptional activity and recruit- ment of coregulators by phytoestrogens. J Biol Chem 2001;276: 17808-14.
  40. Margeat E, Bourdoncle A, Margueron R, Poujol N, Cavailles V, Royer C. Ligands differentially modulate the protein interactions of the human estrogen receptors alpha and beta. J Mol Biol 2003;326: 77-92.
  41. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA. Estrogen receptor beta inhibits 17beta-estradiol-stimulated prolif- eration of the breast cancer cell line T47D. Proc Natl Acad Sci USA 2004;101:1566-71.
  42. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ. HER-2 ty- rosine kinase pathway targets estrogen receptor and promotes hor- mone-independent growth in human breast cancer cells. Oncogene 1995;10:2435-46.
  43. Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Mora- bito A, Pettinato G, Panico L, D'Antonio A, Bianco AR, De Placido S. c-erb B2 overexpression decreases the benefit of adjuvant tamoxi- fen in early-stage breast cancer without auxiliary lymph node metasta- ses. J Clin Oncol 1996;14:2702-8.

Cited by

Sorted by citations

Authors
Suzuki, T., Matsuo, K., Tsunoda, N., Hirose, K., Hiraki, A., Kawase, T., Yamashita, T., Iwata, H., Tanaka, H., & Tajima, K.
Affiliations
  • Aichi Cancer Center Research Institute (JP)
  • Aichi Cancer Center (JP)
  • Aichi Prefectural Institute of Public Health (JP)
Corresponding author
Suzuki, Takeshi
ORCID
Venue
International Journal of Cancer
Publisher
Wiley
Published
2008-07-11
Volume
123
Issue
7
Pages
1674-1680
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
DOI
10.1002/ijc.23644
OpenAlex
W2065778698
Cited by
47
References
2
Citations by year
2026: 1 · 2025: 1 · 2023: 2 · 2022: 2 · 2021: 1 · 2020: 3 · 2019: 1 · 2018: 1 · 2017: 1 · 2016: 2 · 2015: 1 · 2014: 4 · 2013: 6 · 2012: 5
FWCI
3.78
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • International Journal of Cancer (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Ministry of Health, Labour and Welfare
  • Japan Society for the Promotion of Science
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Phytoestrogen effects and research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
  • Health Sciences › Medicine › Oncology › Cancer Risks and Factors
Keywords
soy products, breast cancer risk, estrogen receptor, progesterone receptor, HER2, receptor status, Asian women, cancer prevention
MeSH terms
Adolescent, Adult, Aged, Breast Neoplasms, Humans, Japan, Male, Middle Aged, Receptors, Estrogen, Receptors, Progesterone, Glycine max, Confidence Intervals, Odds Ratio, Case-Control Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review